Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 9/20 | 0.32 |
| ▸ | CA1 | P00915 | 7/20 | 0.32 |
| ▸ | CA9 | Q16790 | 6/20 | 0.32 |
| ▸ | CA12 | O43570 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013623 | 0.79 | HTT (0.37) | — | |
| SCHEMBL20692373 | 0.78 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL22012924 | 0.75 | LOX (0.35) | LOXCA2L3MBTL1 | |
| SCHEMBL21962564 | 0.75 | EDNRB (0.41) | LOXCA2CA1CA9CA12 | |
| SCHEMBL22014389 | 0.72 | CA1 (0.33) | CA2CA1CA4CA5ACA5B | |
| SCHEMBL1548560 | 0.72 | CA2 (0.46) | CA2CA1CA9CA12 | |
| SCHEMBL22012121 | 0.72 | CA1 (0.34) | CA2CA1CA9CA12MMP2 | |
| SCHEMBL29114229 | 0.71 | — | — | |
| SCHEMBL21963133 | 0.70 | CA1 (0.31) | CA2CA1CA4CA5ACA5B | |
| SCHEMBL21963297 | 0.70 | LOXL2 (0.41) | LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |